

Nomination Committee Appointed Ahead of the 2025 Annual General Meeting in Devyser Diagnostics AB

Devyser Diagnostics AB has appointed a Nomination Committee in preparation for the 2025 Annual General Meeting. The Nomination Committee's task is to present proposals to the meeting regarding the election and remuneration of the Board of Directors and auditors, as well as any other matters that may be decided by the Annual General Meeting.

The Nomination Committee for the 2025 Annual General Meeting consists of the following members:

1. Rutger Arnhult, representing M2 Asset Management
2. Caroline Sjösten, representing Swedbank Robur
3. Åsa Riisberg

The Nomination Committee will work in accordance with the guidelines decided at the previous Annual General Meetings. Shareholders who have proposals or requests ahead of the Annual General Meeting may contact the Nomination Committee at agm@devyser.com up until February 14, 2025.

The Annual General Meeting is planned to be held on May 14, 2025 in our facility at Bränningevägen 12, Årsta, Stockholm.

More information regarding the time and place will be announced closer to the meeting.

For more information, please contact:

Sabina Berlin, CFO

Email: ir@devyser.com

Telephone: +46 8 562 158 50



PRESS RELEASE

01 November 2024 12:30:00 CET

About Devyser

Devyser develops, manufactures and sells diagnostic solutions and analysis services to clinical laboratories in more than 65 countries. Our products are used for advanced genetic testing in the hereditary disease, oncology and transplant fields, to enable targeted cancer treatment, the diagnosis of a large number of genetic diseases, and transplant patient follow-up. Devyser's products, and unique, patented solution requiring only one test tube, simplify genetic testing processes, improve sample throughput, minimize hands-on time and deliver rapid results. Our goal is for every patient to receive a correct diagnosis in the shortest possible time. Sustainability is a central part of our business and an important prerequisite for long term value creation.

Devyser was founded in 2004 and is based in Stockholm, Sweden with eight in-house sales offices in Europe and the US. The company also runs Devyser Genomic Laboratories, a CLIA certified laboratory in Atlanta, US. In 2022, Devyser's quality management system was certified according to the IVDR and a number of the company's products have since been certified according to the IVDR.

Devyser's shares are listed on the Nasdaq First North Premier Growth Market Stockholm (ticker: DVYSR). The company's Certified Adviser is Redeye AB.

For more information, visit www.devyser.com.